KKR & Co. closed its $5.89 billion acquisition of Integer Holdings on August 29, taking private a manufacturer that supplies cardiac rhythm devices, neuromodulation components, and vascular products to Medtronic, Abbott, and Boston Scientific. The deal closed at $108.50 per share, a 53% premium to Integer's 90-day volume-weighted average before KKR's approach in May.
Integer generated $1.54 billion in trailing revenue with 22.8% EBITDA margins as of Q2 2024, operating four manufacturing campuses across the U.S., Mexico, and Switzerland. The company holds FDA registrations for 14 facilities and supplies components for approximately 60% of the world's implantable cardiac devices. KKR inherited a order backlog worth $1.1 billion and long-term supply agreements with weighted average durations of 7.2 years.
Healthcare dominated private equity activity in August even as global M&A volume dropped 18% month-over-month to $47.3 billion, according to Refinitiv data. The Integer transaction alone represented 12.4% of total August PE dealflow. KKR's move follows Apollo's $3.7 billion take-private of LifeStance Health in July and Blackstone's $2.2 billion acquisition of AllCare Health in June, marking $11.8 billion in healthcare services and device consolidation across three months.
The strategic value sits in the moat. Integer's customers face 18-24 month product development cycles and regulatory approval timelines that make vendor switching prohibitively expensive. Device manufacturers typically qualify a single primary supplier per component category, embedding Integer into product roadmaps that extend into the next decade. KKR now controls a chokepoint in a supply chain where switching costs exceed $40 million per platform migration, based on industry consultant estimates.
Operators should track two follow-on events. First, whether KKR consolidates Integer with any of the $8.3 billion in medical technology assets already sitting in its Americas XII and Global Impact II funds, specifically Envision Healthcare's ambulatory surgery centers or Heartland Dental's device procurement infrastructure. Second, whether Integer's top-three customers renegotiate supply terms before their contracts roll in 2026-2027, potentially triggering margin compression if they demand price concessions in exchange for extended commitments.
Integer's $427 million in net debt at close gives KKR leverage capacity to bolt on $1.2-1.5 billion in adjacent medtech acquisitions without breaching 5.5x debt-to-EBITDA, the threshold where investment-grade device suppliers historically face rating pressure.